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sus those with 80% adherence. Total expenditures considered expenditures from
inpatient admissions, ER visits, and medications. Potential savings was defined as
reduction in total expenditures due to increasing adherence. RESULTS: Nonadher-
ence resulted in increased all-cause total expenditures in diabetes, cholesterol, and
heart by $240 million (M), $150M, and $47M, respectively. Increasing adherence by
2% reduced increases in all-cause expenditure by 11% to 21%. Nonadherence re-
sulted in increased disease-specific hospitalization and ER visit expenditure for
depression ($6M), diabetes ($44M), and cholesterol ($5M). However, increases in the
disease-specific hospitalization and ER expenditures were offset by lower medica-
tion expenditure, thus resulting in overall lower disease-specific expenditure
among the nonadherent patients. Overall, increases in medication adherence re-
sulted in savings in all-cause expenditure but not in disease-specific expenditure.
CONCLUSIONS: Medication nonadherence can be costly to payers. Increasing ad-
herence even by small amounts may result in significant savings.
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OBJECTIVES: The aim of this study was to estimate prevalence and preventability
of drug-related morbidity in Sweden based on pharmacists’ expert opinion. Fur-
thermore, the aim was to estimate the cost-of-illness (COI) of drug-related
morbidity.METHODS: Probabilities of therapeutic outcomes of medication therapy
were estimated by an expert panel of pharmacists (N29) using a two-round del-
phi-methodology and a conceptual model of drug-related morbidity based on a
decision tree. We used an American conceptual model adjusted to the Swedish
context. In the model, drug-related morbidity included new medical problems (ad-
verse drug reactions, drug dependence and intoxications by overdose) and thera-
peutic failures (insufficient effects of medicines and morbidity due to untreated
indication). The cost-of-illness analysis included all direct costs applying a health
care perspective, using national statistics on costs. RESULTS: The expert panel
estimated that 6114% (mean  SD) of all patients visiting health care suffered
from drug-related morbidity, of which 298% suffered from new medical prob-
lems, 176% from therapeutic failures, and 147% from a combination of both
types. Of patients with drug-related morbidity, 4418% suffered from preventable
drug-related morbidity. Participants estimated that 7-39% of patients with drug-
related morbidity do not require further attention, but a majority requires health
care resources due to the drug-related morbidity. The direct costs were calculated
to EUR 575 (2009 value) per patient, which corresponds to an annual cost of EUR 4
billion to the Swedish health care system. The largest component in the COI of
drug-related morbidity was hospitalizations, with 50% of the total cost. Advanced
specialist care represented 20%, and prolonged hospital stay 11% of the resulting
costs. CONCLUSIONS: Drug-related morbidity is perceived frequent and often pre-
ventable. The estimated health care costs for this morbidity are extensive, and
comparable in magnitude to the cost of dispensed medicines in Sweden. Effective
and cost-efficient methods to reduce the drug-related morbidity are needed.
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OBJECTIVES: Controlling pharmaceutical costs has been the subject of research
and analysis in many studies in health economics which have shown that the
chronic conditions of patients are an important factor. The present work models
pharmaceutical expenditure by different health districts and gender according to
the characteristics of chronic conditions. METHODS: An analysis was made of
pharmaceutical expenditure between November 2008 and October 2009 of four
health districts of the Autonomous Valencian Government, with an assigned pop-
ulation of 625,246. Those who had followed treatments for chronic conditions were
identified associating the pharmaceutical groups (ATC codes) with 24 chronic con-
ditions, according to electronic prescription data. Multivariate regression analysis
was used, where the pharmaceutical expenditure in primary health care was ex-
plained through the gender, pharmaceutical co-payment status and the number of
chronic conditions, varying from 1 to 8 or more. RESULTS: The percentage of pa-
tients with chronic conditions obtained was of 27.82%, who constituted 58.2% of
the total pharmaceutical cost. Pharmaceutical co-payment status was excluded
from the model due to its high correlation with the number of chronic conditions.
The goodness of fit obtained for explaining the expenditure of the whole popula-
tion was of 57.2%. The models obtained by health district explained between 56.5
and 60.6%, improving in the models obtained solely for the male population, where
they reached 62% for one of the districts studied. Men’s pharmaceutical expendi-
ture was the 68.31% of women’s. However, the number of chronic conditions has a
greater impact on men’s pharmaceutical expenditure than women’s.
CONCLUSIONS: Although for the whole population the proposed model explained
the 57.2% of the pharmaceutical expenditure, differences can be observed between
models obtained for each district or for gender. These models may be more suitable
than the general model for cost management and establishing incentives for gen-
eral practitioners in the different districts.
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OBJECTIVES: Taipei Medical University Shuang-Ho Hospital officially opened on
July 1, 2008. Due to limited revenue during the initial period, hospital emphasized
more on cost control. With the great demand of medication from the growing
numbers of outpatients visits and inpatients, pharmacy aim to establish an opti-
mal purchase model to minimize drug inventory management cost. METHODS:
Economic Order Quantity (EOQ) model were applied to find out the best quantity
and frequency on medication purchase order. We analyzed the high-cost medica-
tions in which the top 50% of cumulative drug cost in year 2010, and intravenous
antineoplastic drugs were excluded. RESULTS: The study evaluate drug cost, labor
cost and inventory cost. Forty-six high-cost medications were selected to deter-
mine EOQ model in this study. The optimal frequency to order each drug estimated
by EOQ model was three to ten times per month. The estimated cost of inventory
management reduced substantially when order more frequently within 10 times a
month. However, after considering the practicability in real practice, the order
frequency was adjusted to one to four times per month. The best estimated quan-
tity for each drug was also adjusted by previous fluctuation of purchase orders
during 2010. Therefore, the estimated inventory management cost in year 2011
could reduce 500,000 to 700,000 NTD CONCLUSIONS: Our inventory management
currently purchase drug twice a month. In order to optimize inventory turnover
rate, without increasing pharmacists work loading and management cost, we rec-
ommend adjusting quantity and frequency of ordering medication based on our
finding to achieve the minimal and rational cost on inventory management.
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Due to the financial crisis, Greece was forced by the International Monetary Fund
and the European Community (Troika) to implement cost containment measures
in the health care sector. OBJECTIVES: The objective of the study is to present the
measures taken in order to control and reduce the pharmaceutical expenditure in
all NHS hospitals and evaluate the respective savings emerging in 2010.METHODS:
The data derive from the Ministry of Health and Social Solidarity (MoH) database,
covering all NHS & IKA hospitals operating in the 7 Regional Health Authorities
(RHA) of Greece. Data compare the NHS hospital pharmaceutical expenditure be-
tween 2009 and 2010. RESULTS: Numerous cost-containment measures have been
gradually implemented in all NHS hospitals according to the IMF and MoH guid-
ance, targeting at: 1)creation of NHS database network (esy.net); 2)transfer of the
pharmaceutical pricing regulation from the Ministry of commerce to the MoH;
3)unification of the NHS electronic coding system, for ordering and prescribing of
pharmaceuticals; 4)hospital packsize; 5)electronic patients files; and 6)increase in
the use/penetration of generics & off patent medicines. Although the above mea-
sures are still not fully implemented, they reduced hospital pharmaceutical expen-
diture by 10.51%, from €1.466 million in 2009 to €1.312 million in 2010. At regional
level, savings ranged from 8% in the 2nd RHA (covering Pireaus & islands) up to 16%
in 6th RHA (Peloponnese & Western Greece). Moreover, in the 1st RHA covering the
highest share of NHS hospitals of pharmaceutical expenditure was reduced by 15%.
CONCLUSIONS: The new cost containment measures implemented in Greek NHS
hospitals started presenting results by fulfilling the savings imposed by IMF &
Troika). The same picture is presented in the overall HC sector, hospitals & social
security funds. The goal of €350million savings by the NHS hospitals seems to be
able to be achieved by the end of 2011.
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OBJECTIVES: In Switzerland, emergency care has no gatekeeping system and
emergency wards are increasingly overcrowded by walk-in patients. This leads to
inefficient use of spezialised resources. Treatment costs are paid by public sources
and, beyond some co-payment, reimbursed by health care insurances via tariffs.
Given the problems above, a public hospital (Stadtspital Waid; Zurich; catchment
population 180’000 people) reorganised its emergency service in 2008. A nurse led
triage system and a General Practitioner-led emergency service was implemented
beside the conventional emergency ward. To better understand the impact, we
assessed quality of service provision and total treatment costs. METHODS: From
the public payer perspective, we compared annual treatment costs for ambulatory
emergency care in 2007 with 2009. In a pre-post study, all consecutive ambulatory
emergency patients were included during one month in each year. Treatment costs
(CHF) were calculated (e.g. nursing time multiplied with wages) and extrapolated to
one year. Waiting times and patient satisfaction were used as indicators for service
quality. Clinical outcome was not directly measured. RESULTS: The annual num-
ber of ambulatory patients increased from n10’440 (2007) to n16’035 (2009).
Service provision improved with reduced waiting times (mean: 120 min vs. 60 min),
persistently high patient satisfaction and more efficient resource use (additional
diagnostic testing: 71% vs. 56%). Comparison of the annual local budget spent for
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treatment of 16,035 patients in 2009 (7,150,000 CHF; new service) with 2007
(7,184,000 CHF; old service, adjusted to 16,035 patients) showed slightly reduced
costs (-34,000 CHF; 95%-CI:60,000 to -127,000).CONCLUSIONS:The cost reduction
of 0.5% is a conservative estimate as wages have increased since 2007. The reor-
ganisation has the potential to be a dominant intervention: While quality of service
provision improved, treatment costs slightly decreased against the secular trend of
increase. Data has to be confirmed in follow-up measurements for decision mak-
ers.
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OBJECTIVES: The Stability and Growth Pact approved by the Portuguese Govern-
ment in 2010 limits the expenditure growth in 1% for reimbursed pharmaceuticals
in outpatient sector. The Memorandum of Understanding signed in May 2011 be-
tween the Government and the International Authorities subsequently has in-
creased the requirements to reduce public expenditure. Considering the pricing
and reimbursement changes, this study aims to: 1) analyze public expenditure
trends on medicines, and 2) identify the main factors and impacts. METHODS: We
have analyzed the database sales and prescription data from Portuguese commu-
nity pharmacies, and performed simulations to measure the impact of policy mea-
sures. The statistical analysis of monthly data by product was performed with SAS.
RESULTS: The NHS expenditure in outpatient medicines has increased 5.6% in
2010. The legislation approved in June 2009, that established generics reimburse-
ment at 100% for some pensioners (withdrawn in June 2010), was responsible for
more 26.8 million euros of NHS spending in 2010. Nevertheless 117.1 million euros
were explained by new molecules reimbursed in the last three years. After July 2010
and due to the 1% VAT increase, the expenditure had increased 7.5 million euros.
The Health Subsystems (special security schemes for certain professions) had also
contributed positively: in December about 7.4 million euros were transferred from
the ‘ADSE’ (civil servants subsystem) for NHS. At the end of 2010, the Government
adopted further measures to control public expenditure, such as 6% prices deduc-
tion and several reductions in pharmaceuticals reimbursement levels. Immedi-
ately the NHS medicines expenditure decreased 21.2% in the four first months of
2011. In opposition the hospital market is growing 3.5%. CONCLUSIONS: Besides
price and reimbursement administrative reductions, with limited impact in the
short run, it would be important to consider measures, that should be assessed on
a periodic basis to identify the best strategies to promote rationality and efficiency
in the outpatient and hospital sector.
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OBJECTIVES: To compare the use of health care services between patients with
private and public drug insurance among users of anti-depressants. METHODS: A
matched retrospective cohort study was conducted using databases for Quebec
residents with private (reMed database) or public (RAMQ database) drug insurance.
The study included 194 reMed and 1923 RAMQ patients aged 18 to 64 years who
filled at least one prescription of an antidepressant between December 2007 and
September 2009. Patients were matched on age, sex and date of 1st filled prescrip-
tion of an antidepressant. The primary outcomes were the number of outpatients
medical visits, emergency department (ED) visit (yes/no) and hospitalization (yes/
no) for all causes over one year. The secondary outcome was the average antide-
pressant cost per patient per month. Linear or logistic regression was used to
compare the outcomes between patients with private and public drug insurance,
while adjusting for potential confounders. RESULTS: Patients with private drug
insurance (21.3% males) had 8.1 outpatient medical visits on average, 17.5% had an
ED visit and 8.8% were hospitalized over one year. Corresponding figures were 6.6,
20.0% and 8.5% for patients with public drug insurance (23.6% males). Patients with
private drug insurance were found to have more outpatient medical visits than
patients with public drug insurance (adjusted mean difference 1.2; 95%CI: 0.2 to
2.3), but were not more likely to have an ED visit (adjusted OR 0.7; 95% CI: 0.5 to 1.1)
or a hospitalization (OR0.9; 95%CI: 0.5-1.6). Average cost per patient per month for
antidepressants was $48.50 (95%CI: 44.97-52.02) and $33.73 (95%CI: 32.94-34.51) for
patients with private and public drug insurance, respectively. CONCLUSIONS: Lit-
tle differences were found in the use of health care services between users of
antidepressants with private and public drug insurance, while important differ-
ences were observed for the cost of antidepressants.
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OBJECTIVES: To explore the current status (2010) of tendering programs for outpa-
tient pharmaceuticals in the European countries and how these programs operate.
METHODS: A survey was designed to assess the features of tendering programs in
European countries. All 27 countries of the European Union plus Norway were
included in the study. The survey was sent to national representatives of authori-
ties and organizations and to academic researchers with expertise in the domain.
RESULTS: Nineteen of the 28 countries have responded to the questionnaire (68%).
Seven countries have adopted tendering programs for pharmaceuticals in ambu-
latory care. Tendering was more popular in countries with a mature generic med-
icines market (54%) than in countries with a developing generic medicines market
(12.5%). Authorities with financial interest for possible savings issued the tenders
and the lowest price/best offer was amongst the criteria to award the tender in
most cases. The frequency varied from only once to once every two weeks and the
number of winners was between one and four. The objectives of achieving cost
savings were achieved in the short term but results on long term are still unclear.
CONCLUSIONS: Tendering programs can achieve savings in the short term, but the
effects in the long term are still unclear. It can be concluded that the policy can
work, but the features of the programs such as the legal framework, the criteria to
grant the tender, the number of winners, the reward of the winner and the fre-
quency, have to be well-thought-out.
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OBJECTIVES: To assess the performance in seven homogenous specialty clinics
across all NHS hospitals in the Regional Health Authority of Thessaly (RHAT), over
the period 2002-2006. METHODS: Data Envelopment Analysis by using the
Malmquist Productivity Index and its decompositions have been applied in order to
measure the technical efficiency and productivity. Clinics were considered to
transform inputs labour (medical and nursing staff) and capital (hospital beds) into
health services, approximated by the number of in-patient discharges and in-pa-
tient days, used as outputs. The model is output oriented and assumes variable
return to scale. Data were collected from hospitals’ records. RESULTS: Overall pro-
ductivity progressed in all clinics, led by technical change rather than technical
efficiency. Over the whole period the size of the clinics influences the overall effects
on hospital performance and the maximum level of outputs produced has not been
achieved using the given labour and capital inputs, except orthopaedic clinics. The
highest productivity changes were achieved by the gynecology (22.5%), the urology
(15.7%) and the paediatric clinics (15.4%). All clinics experienced high technological
change level, except general medicine clinics which drops by 6.5%. The highest
technological changes were experienced by gynecology clinics (48.4%), the paedi-
atrics (26.2%) and ophthalmology (22.1%). CONCLUSIONS: Homogeneity in assess-
ing hospitals’ performance provides evidence on the efficiency and productivity
gains among clinics and suggests improvements in those which appear inefficient.
The difficult economic situation Greece is facing nowadays makes the assessment
of NHS hospitals’ performance a priority in the decision making.
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OBJECTIVES: Muscle relaxants are used in anesthesia to obtain adequate muscle
relaxation. Our aim is obtaining improvement in hospital budget by selecting ad-
equate neuromuscular blocking agents for short-term (under 60 minutes)pediatric
operations for hospital managements. METHODS: There is a basic investigation of
the duration to recovery time of atracurium and rocuronium administrations dur-
ing anesthesia induction in ASA I-II children. In order to evaluate the effect on
hospital budget, direct expenses were used. RESULTS: The mean time to reach
TOF75 in recovery with rocuronium and atracurium were calculated 38 and 51
minutes, respectively. In atracurium group, time to reach TOF75 was 51 minutes,
but operation time was 46 minutes(as rocuronium groups)and patients needed an
additional 5 minutes for recovery. During additional minutes, patients were kept in
the operation room(OR), thus preparation for the next patient was delayed. After
extubation of patients, to determine the period of preparation of an OR for the next
patient, a questionnaire was administered. This preparation was determined to be
14 minutes. These means, in the rocuronium and atrocurium groups one needs 60
minutes (4614) and 65 minutes (5114), respectively from the start of an opera-
tion to the start of next operation. In a pediatric surgery department, lower abdom-
inal and urogenital surgery unit income with rocuronium or atracurium are the
same but, rocuronium brings extra time for an average of 15 operations lasting
shorter than 1 hour. CONCLUSIONS: Study showed that if a hospital works with
100% performance and has no other problems (shortage of bed,personnel,etc), such
a hospital may perform, in a month, an extra 15 pediatric surgical operations less
than 1 hour can, by using rocuronium. Thus rocuronium may lead an additional
income of US$ 2436 per month for one OR. In other words, in short operations, using
rocuronium rather than atracurium may lead to savings which is 30-35% of total
cost.
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